How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?

Expert Rev Neurother. 2014 Nov;14(11):1251-60. doi: 10.1586/14737175.2014.962517. Epub 2014 Sep 22.

Abstract

Tuberculosis continues to be a serious health problem worldwide. The disease continues to be underdiagnosed and not properly treated. In conditions that affect the immune system, such as multiple sclerosis (MS), latent tuberculosis may thrive and reactivate during the use of immunomodulatory and immunosuppressive drugs. Among the best treatment options for patients with latent or active tuberculosis who have MS are IFN-β, glatiramer acetate and mitoxantrone. Drugs leading to a reduced number and/or function of lymphocytes should be avoided or used with caution. Tuberculosis must always be investigated in patients with MS and treated with rigor.

Keywords: IFN-β; fingolimod; fumarate; glatiramer acetate; multiple sclerosis; natalizumab; teriflunomide; tuberculosis.

Publication types

  • Review

MeSH terms

  • Disease Management
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Multiple Sclerosis / drug therapy*
  • Tuberculosis / etiology*

Substances

  • Immunosuppressive Agents